Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
July 2019
-
Media ReleaseNovartis data show Aimovig® cuts acute migraine medication days by half in patients who failed prior preventive therapiesData from the active treatment phase of STRIVE investigated efficacy and safety of Aimovig (erenumab) 70 and 140 mg in episodic migraine patients with prior preventive treatment failures …
-
Media ReleaseNovartis data underpin long-term efficacy of Aimovig® where other treatments have failedData from LIBERTY demonstrated sustained efficacy of Aimovig (erenumab) 140 mg in reducing monthly migraine days (MMD) at 13-24 weeks in episodic migraine patients with 2-4 prior preventive…
June 2019
-
Media ReleaseNovartis highlights new publication showing IL-17A antibody Cosentyx® improves inflammation and rapidly suppresses IL-23 in plaque psoriasisNew data show that Cosentyx modulates gene expression leading to substantial improvement of inflammation, as early as Week 12 by reversing plaque histopathology in the majority of patients[1]…
-
Flexibility at Novartis: Christine Sturchler and Aileen Wrynn
Sturchler and Wrynn explain why their job-sharing experience was one of the most successful and energizing periods of their careers.
-
Media ReleaseNovartis provides update on phase 2b ENCORE-LF trial in NASH cirrhosisConatus today announced top-line results from the ENCORE-LF trial, which did not meet its primary endpoint Novartis remains fully committed to pursuing the development of multiple compounds in…
-
Featured NewsWorld Sickle Cell Day 2019
For over 40 years Novartis has been committed to understanding sickle cell disease and working towards treatment.
-
Media ReleaseNew analysis of Novartis data confirms that Cosentyx® demonstrates durable comprehensive treatment across psoriatic diseaseFor the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx® as comprehensive treatment across multiple manifestations of…
-
Media ReleaseNew Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacyData show switching to Hyrimoz® (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis[…
-
Media ReleaseNovartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001)Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many…
-
Media ReleaseThree quarters of people living with axial spondyloarthritis struggle to find a job, IMAS survey showsNew European data from IMAS survey show that people living with axial spondyloarthritis (axSpA) suffer a delay in diagnosis of over 7 years, potentially leading to an increase in work-related…
-
Media ReleaseCosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data showAlmost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg[1] Data at 2 years demonstrate over 50% of adults with…
-
Media ReleaseNovartis Cosentyx® first to show efficacy in all key manifestations of psoriatic arthritisFirst-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide[1…
Pagination
- ‹ Previous page
- 1
- …
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- …
- 152
- › Next page